Francesca Devine

ORCID: 0000-0001-9689-4659
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Herpesvirus Infections and Treatments
  • Cytomegalovirus and herpesvirus research
  • COVID-19 and healthcare impacts
  • Cancer Risks and Factors
  • Pharmacological Effects of Natural Compounds
  • Blood Pressure and Hypertension Studies
  • Bladder and Urothelial Cancer Treatments
  • Schizophrenia research and treatment
  • Hematological disorders and diagnostics
  • Treatment of Major Depression
  • Acne and Rosacea Treatments and Effects
  • Health Systems, Economic Evaluations, Quality of Life
  • Systemic Lupus Erythematosus Research
  • Bartonella species infections research
  • Multiple and Secondary Primary Cancers

Analysis Group (United States)
2022-2023

ABSTRACT Objective Outcomes in pregnancies with rare autosomal aneuploidies (RAAs) are poorly characterized, most studies having small sample sizes. Here, we describe outcomes and management a large cohort of that screened positive for an RAA (RAA+). Methods Results prenatal cell‐free DNA screening were linked to de‐identified insurance claims data. Diagnosis procedure codes used estimate pregnancy management. Relevant covariates comparative analyses adjusted using propensity‐score matching....

10.1002/pd.6776 article EN cc-by-nc-nd Prenatal Diagnosis 2025-03-23

Objective To estimate the incidence of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) compared general population USA. Methods This retrospective, longitudinal cohort study used data from an administrative claims database containing both commercial and Medicare Advantage Part D data, a period October 2015 to February 2020. Patients were aged ≥ 18 years divided into 2 cohorts: RA without RA. Diagnosis procedure codes identify HZ cases calculate rates (IRs) cohorts. Data...

10.3899/jrheum.220986 article EN The Journal of Rheumatology 2023-02-01

To estimate the incremental healthcare resource utilization (HRU) and cost burden posed by herpes zoster (HZ) in adult patients with rheumatoid arthritis (RA) United States.A retrospective cohort study was conducted using an administrative claims database containing commercial Medicare Advantage Part D data, between October 2015 February 2020. Patients RA HZ (RA+/HZ+) or without (RA+/HZ-) were identified based on diagnosis codes relevant medications. Outcomes measured included HRU medical,...

10.1007/s40744-023-00549-x article EN cc-by-nc Rheumatology and Therapy 2023-05-23

Evaluate clinical characteristics, comorbidity burden, major depressive disorder (MDD)-related healthcare resource utilization (HCRU), medication and antidepressant treatment (ADT) patterns among older adults with MDD without selected comorbidities.

10.1080/03007995.2024.2348603 article EN cc-by-nc-nd Current Medical Research and Opinion 2024-05-02

Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ). We evaluated the incidence HZ in ulcerative colitis (UC) and Crohn's (CD) patients compared this a non-IBD population.We conducted retrospective cohort study (GSK identifier: VEO-000043) adults aged ≥18 years UC CD without IBD who were identified from claims recorded US healthcare database between October 2015 February 2020. Crude rates/1,000 person-years (PY) calculated, comparisons rates or cohorts...

10.1093/gastro/goad016 article EN cc-by Gastroenterology report 2022-12-30

Patients with ulcerative colitis (UC) or Crohn's disease (CD) are at increased risk of herpes zoster (HZ); however, relevant cost and healthcare resource utilization (HCRU) data limited.We estimated HCRU (hospitalization, emergency department [ED], outpatient visits) costs in patients UC CD, without HZ, using administrative claims (October 2015-February 2020). (2020 US dollars) were compared 1 month, quarter, year after the index date, propensity score adjustment generalized linear models.In...

10.1093/crocol/otad033 article EN cc-by Crohn s & Colitis 360 2023-07-01

e13757 Background: Despite the aggressive nature of breast cancer (BC) among women under 45 years old, racial disparities in BC care still exist. The COVID-19 pandemic highlighted management. This study described staging, treatment use, and healthcare resource use (BC-HCRU) reproductive-aged White, Asian, Black before after to identify possible changes. Methods: retrospective claims assessed aged 18 44 old with newly diagnosed Komodo Research Dataset from August 2018-May 2023. Women were...

10.1200/jco.2024.42.16_suppl.e13757 article EN Journal of Clinical Oncology 2024-05-29

11038 Background: Given the broad exclusion of pregnant patients from clinical trials, limited evidence exists on impact cancer diagnoses pregnancy outcomes. This study aimed to describe patient characteristics and end events among women with without a diagnosis before pregnancy. Methods: retrospective claims used data Komodo Research Dataset between 01/01/2016–08/31/2023 identify adult known gestation record outcome. Eligible members needed be continuously enrolled in medical prescription...

10.1200/jco.2024.42.16_suppl.11038 article EN Journal of Clinical Oncology 2024-06-01

e16500 Background: Bladder cancer is the sixth most prevalent malignancy in United States, of which urothelial carcinoma (UC) predominant histologic type. The prognosis metastatic UC (mUC) generally poor with standard platinum-based chemotherapy (PBC) regimens. With approvals immunotherapy (IO) and antibody drug conjugates (ADCs) recent years, treatment landscape has been evolving substantially. This study aimed to describe current, real-world patterns mUC. Methods: retrospective used...

10.1200/jco.2024.42.16_suppl.e16500 article EN Journal of Clinical Oncology 2024-06-01
Coming Soon ...